Johnson & Johnson
Change company Symbol lookup
Select an option...
JNJ Johnson & Johnson
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
AEG Aegon NV
MGP MGM Growth Properties LLC
Go

Health Care : Pharmaceuticals | Large Cap Value
Company profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Closing Price
$164.96
Day's Change
-2.12 (-1.27%)
Bid
--
Ask
--
B/A Size
--
Day's High
167.08
Day's Low
164.22
Volume
(Average)
Volume:
7,389,922

10-day average volume:
6,860,986
7,389,922

CLASS ACTION UPDATE for ATNX, RMO and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

6:30 am ET May 3, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / May 3, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ATNX Shareholders Click Here: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=15385&wire=1

RMO Shareholders Click Here: https://www.zlk.com/pslra-1/romeo-power-inc-loss-submission-form?prid=15385&wire=1

ACAD Shareholders Click Here: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=15385&wire=1

* ADDITIONAL INFORMATION BELOW *

Image: https://www.accesswire.com/users/newswire/images/643812/ZLK_PR_Logo-3.png

Athenex, Inc. (NASDAQ:ATNX)

ATNX Lawsuit on behalf of: investors who purchased August 7, 2019 - February 26, 2021

Lead Plaintiff Deadline : May 3, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/athenex-inc-loss-submission-form?prid=15385&wire=1

According to the filed complaint, during the class period, Athenex, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the data included in the Oral Paclitaxel plus Encequidar NDA presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (ii) the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by BICR; (iii) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (iv) the Company's Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (v) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Romeo Power, Inc. (NYSE:RMO)

RMO Lawsuit on behalf of: investors who purchased October 5, 2020 - March 30, 2021

Lead Plaintiff Deadline : June 15, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/romeo-power-inc-loss-submission-form?prid=15385&wire=1

According to the filed complaint, during the class period, Romeo Power, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Romeo had only two battery cell suppliers, not four, (ii) the future potential risks that Defendants warned of concerning supply disruption or shortage had already occurred and were already negatively affecting Romeo's business, operations and business prospects, (iii) Romeo did not have the battery cell inventory to accommodate end-user demand and ramp up production in 2021, (iv) Romeo's supply constraint was a material hindrance to Romeo's revenue growth, and (v) Romeo's supply chain for battery cells was not hedged, but in fact, was totally at risk and beholden to just two battery cell suppliers and the spot market for their 2021 inventory. Given the supply constraint that Romeo was experiencing during the Class Period, Defendants had no reasonable basis to represent that the Company had the ability to meet customer demand and that it would support growth in revenue in 2021.

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)

ACAD Lawsuit on behalf of: investors who purchased June 15, 2020 - April 4, 2021

Lead Plaintiff Deadline : June 18, 2021

TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=15385&wire=1

According to the filed complaint, during the class period, Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com

SOURCE: Levi & Korsinsky, LLP

View source version on accesswire.com:

https://www.accesswire.com/643812/CLASS-ACTION-UPDATE-for-ATNX-RMO-and-ACAD-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.